My hope is that the cap raise money is;
A. funding the current research and we are getting leveraged value (we pay the research, Otsuka supplies the drugs);
B. the research will be successful (historic results, mouse models and Mason's meta analysis suggest it will be);
C. the passing time and potential buyout provide CGT discounts that might outweigh the cheaper prices now available because we may have later missed out on a discount? (it's already a year since I put into the soph raise at $3 last May, so I'm ready for a buyout!)
Tough times at the moment.
RAC - Charts & Price Action, page-11814
-
- There are more pages in this discussion • 11,120 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.020(1.37%) |
Mkt cap ! $258.2M | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.52 | $1.49 | $96.94K | 64.49K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 312 | $1.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 7659 | 3 |
View Market Depth
| Last trade - 12.24pm 04/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |